New study supports safety of COVID-19 vaccines for pregnant, lactating women miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Newswise Boston – Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age women. Increases in preterm birth and still birth have also been observed in pregnancies complicated by the viral infection. The Centers for Disease Control and Prevention (CDC) recommended that people who are pregnant may choose to be vaccinated at their own discretion with their healthcare provider. However, pregnant and lactating women were not included in Phase 3 vaccine efficacy trials; thus, data on vaccine safety and immunogenicity in this population is limited.
In a new study from Beth Israel Deaconess Medical Center (BIDMC), specialists in the Department of Obstetrics and Gynecology and the Center for Virology and Vaccine Research evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. The resea
This figure presents serum binding and functional antibody responses following COVID-19 vaccination and SARS-CoV-2 infection among women 45 years or younger.
A and B, Each panel compares vaccine antibody responses at 2 through 8 weeks after the second dose to nonpregnant and pregnant women who were unvaccinated and infected. Thirteen women (7 nonpregnant, 4 pregnant, and 2 lactating) who had baseline samples collected within 7 days of their first vaccine dose were selected based on the earliest sample availability and were analyzed as a negative assay control.
C, D, and E, Systems serology was used to quantify spike-specific antibody–dependent neutrophil phagocytosis (ADNP), antibody–dependent complement deposition (ADCD), and antibody–dependent monocyte cellular phagocytosis (ADCP).
E-Mail
Boston - Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age women. Increases in preterm birth and still birth have also been observed in pregnancies complicated by the viral infection. The Centers for Disease Control and Prevention (CDC) recommended that people who are pregnant may choose to be vaccinated at their own discretion with their healthcare provider. However, pregnant and lactating women were not included in Phase 3 vaccine efficacy trials; thus, data on vaccine safety and immunogenicity in this population is limited.
In a new study from Beth Israel Deaconess Medical Center (BIDMC), specialists in the Department of Obstetrics and Gynecology and the Center for Virology and Vaccine Research evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. The researc
Amanda Kallen, MD
Dr. Amanda N. Kallen is a Yale Medicine
reproductive endocrinologist and an assistant professor of obstetrics and gynecology at the Yale School of Medicine, as well as a member of the Reproductive Scientist Development Program (RSDP). She obtained her medical degree at the University of Connecticut and completed her residency in obstetrics and gynecology at Yale-New Haven Hospital, followed by a fellowship in reproductive endocrinology and infertility at the Yale School of Medicine. During her fellowship, she was accepted into the RSDP scholar program, an NIH-funded physician-scientist training program committed to training young obstetrician-gynecologists in biomedical science. Dr. Kallen’s current research program is focused on the investigation of the regulation of gene expression in granulosa cells. Her clinical interests include pediatric and adolescent gynecology and endocrinology, infertility, and premature ovarian insufficiency. Dr. Kallen is highly acti